The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global immunoglobulin market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 7% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Also known as antibodies, immunoglobulins refer to a class of glycoprotein molecules produced by plasma or white blood cells (WBCs). They are generally present in the serum and cells of the immune system and function as antibodies by explicitly recognizing and binding antigens, such as bacteria or viruses, and aiding in their destruction. Their tests help doctors diagnose immunodeficiencies, allergies, and autoimmune conditions like juvenile idiopathic arthritis, lupus, and celiac disease. At present, different classes of immunoglobulins are available around the world depending on biological features, structure, target specificity, and distribution.
Due to rapid urbanization and hectic schedules, there is a rise in the consumption of fast food among individuals. This, along with sedentary lifestyles and the increasing number of patients with medical conditions like multiple myeloma, Waldenstrom macroglobulinemia, and autoimmune disorders, represents one of the primary factors impelling the growth of the market. Additionally, rising awareness about early diagnosis and the increasing preferences for personalized medicines are contributing to market growth. Moreover, immunoglobulins through a variety of routes of administration help the body fight various infectious diseases. As a result, with the rising number of hospitalized patients with coronavirus disease (COVID-19) and an urgent need for effective therapies to prevent the spread of the pandemic, hyperimmune globulin is utilized as an effective medicine in managing the infection. Apart from this, several pharmaceutical companies are introducing new and advanced immunoglobulins with improved efficiency for the treatment of neurological disorders. Other factors, such as increasing funding for research and development (R&D) projects and the improving healthcare infrastructure are anticipated to propel the market growth further in the coming years.
IMARC Group provides an analysis of the key trends in each sub-segment of the global immunoglobulin market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on product, application and mode of delivery.
Breakup by Product:
Breakup by Application:
Breakup by Mode of Delivery:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being ADMA Biologics Inc., Baxter international Inc., Biotest AG, CSL Limited, Grifols S.A, Kedrion S.p.A, LFB SA, Octapharma AG, Sanquin Plasma Products B.V. and Takeda Pharmaceutical Company Limited.
|Base Year of the Analysis||2020|
|Segment Coverage||Product, Application, Mode of Delivery, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||ADMA Biologics Inc., Baxter international Inc., Biotest AG, CSL Limited, Grifols S.A, Kedrion S.p.A, LFB SA, Octapharma AG, Sanquin Plasma Products B.V. and Takeda Pharmaceutical Company Limited.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at